Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma

Adamo, Vincenzo; Ferraro, Giuseppa; Pergolizzi, Stefano; Sergi, Concetta; Laudani, Agata; Settineri, Nicola; Alafaci, Elisabetta; Scimone, Antonino; Spanò, F.; Spitaleri, Gianluca

doi:10.1016/j.oraloncology.2003.10.010

Cited by 41 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the time of study design the standard chemotherapy regimen using doublets was cisplatin/5 fluorouracil but both prospective [10,11] and randomized studies demonstrated that there was neither a difference in overall survival nor in response rate between cisplatin/5 fluorouracil and cisplatin/paclitaxel [12] in recurrent or metastatic HNSCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study

et al. 2011

Self Cite

View full text Add to dashboard Cite

Backgroundto evaluate activity and toxicity of a sequential treatment in advanced, non metastatic, mostly unresectable, head and neck squamous cell carcinoma.MethodsPatients with loco-regionally advanced or unresectable, head and neck cancer, were prospectively treated with 3 courses of induction chemotherapy followed by concurrent chemoradiation. Induction chemotherapy consisted of paclitaxel 175 mg/m2 day 1 and cisplatin 75 mg/m2 day 2, given every 3 weeks, to a total of three courses. Curative radiotherapy started 4 weeks after the last cycle of chemotherapy with the goal of delivering a total dose ≥ 66 Gy. During RT weekly paclitaxel (40 mg/m2) was administered.ResultsThe trial accrued 43 patients from January 1999 to December 2002. All patients received 3 courses of induction chemotherapy and the planned dose of radiotherapy. Thirty-eight patients were able to tolerate weekly paclitaxel during irradiation at least for 4 courses. After induction therapy there were 32 overall responses, 74.4% (23 partial and 9 complete); at completion of concomitant treatment overall responses were 42, 97.7% (20 partial and 22 complete). Median time to treatment failure was 20 months and the disease progression rate at 3 and 5 years was 33% and 23%, respectively. The median overall survival time was 24 months and 3 and 5 years overall survival rates were 37% and 26%, respectively. The major toxicity was mucositis.ConclusionsThis combined treatment was found to be feasible and active in advanced or unresectable, head and neck squamous cell carcinoma patients. Long-term results observed in this trial encourage to consider this approach in further investigation using newer radiation delivering technique and new molecularly agents.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Newer chemotherapeutic agents, such as paclitaxel, have been successfully integrated both in recurrent and metastatic HNSCC [10-12]; besides weekly paclitaxel can be safely combined with conventionally fractionated and hyperfractionated radiation [13,14]. …”

Section: Introductionmentioning

confidence: 99%

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several large studies have compared single chemotherapeutic agents with two agent combination therapy and, in general, have found that combination treatment is superior in response rates and as palliative therapy but does not improve overall survival [36,37]. More recently, promising results from studies of taxane compounds (paclitaxel and docetaxel) in combination with cisplatin [38-40] have prompted a direct comparison with 5-FU and cisplatin (FC) for recurrent and metastatic disease. However, the results from this study indicated that paclitaxel and cisplatin (PC) did not provide any improvement in response rate (29.8% FC vs 26% PC) or survival (median survival 8.7 months FC vs 8.1 months PC) when compared to FC [41].…”

Section: Existing Treatmentmentioning

confidence: 99%

Emerging drugs to treat squamous cell carcinomas of the head and neck

Fung

Grandis

2010

Expert Opinion on Emerging Drugs

100

113

View full text Add to dashboard Cite

Importance of the field Head and neck squamous cell carcinoma (HNSCC) is the eighth leading cause of cancer death worldwide. Despite advances in surgery and chemoradiation therapy, there has been little improvement in survival rates over the past 4 decades. Additionally, surgery and chemoradiotherapy have serious side effects. The development of agents with greater efficacy and tolerability is needed. Areas covered in this review EGFR is the only proven molecular target for HNSCC therapy. Cetuximab, the sole FDA-approved molecular targeted HNSCC therapy, and other potential targeted therapies are being evaluated in preclinical, clinical and post-marketing studies. Here, we review the emerging targets for biological agents in HNSCC and the rationale for their selection. What the reader will gain Key information in the development of new drug targets and the emergence of new biomarkers are discussed. Readers will gain insight regarding the limitations of current therapies, the impact of recently approved targeted therapies and the influence that predictive biomarkers will have on drug development. Take home message The head and neck cancer drug market is rapidly evolving. Coordination between drug and biomarker development efforts may soon yield targeted therapies that can achieve the promise of personalized cancer medicine.

show abstract

“…In patients with recurrent and/or metastastic SCCHN (R/MSCCHN), a recent study showed that the combination of paclitaxel and cisplatin resulted in an overall response rate of 41.1% (CRR 6%) and a median overall survival of 11 months (range 1-53 months) with mild toxicity [11]. In the same patient population, the combination of paclitaxel-cisplatin (TP) was compared with the standard PF schedule and showed a comparable efficacy (response rate 22% versus 18%, median survival 8 months versus 9 months; 1-year survival 41% versus 30%), with less toxicity.…”

Section: Paclitaxel and Platinum Compoundsmentioning

confidence: 99%

Taxanes in the treatment of head and neck cancer

Schrijvers

Vermorken

2005

Current Opinion in Oncology

View full text Add to dashboard Cite

Both docetaxel and paclitaxel can be combined with chemotherapeutic agents and radiotherapy, but phase III studies are needed to prove the superiority of these approaches compared to standard treatment. The final results of the combination study of cisplatin and 5-fluorouracil with or without docetaxel may change the standard chemotherapeutic regimen for induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.

show abstract

Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma

Cited by 41 publications

References 20 publications

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study

Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study

Emerging drugs to treat squamous cell carcinomas of the head and neck

Taxanes in the treatment of head and neck cancer

Contact Info

Product

Resources

About